查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992818

感染疾病物市場：2026-2032年全球市場預測（依產品類型、適應症、給藥途徑、通路和最終用戶分類）

Anti-infectives Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，感染疾病物市場價值將達到 1,383.7 億美元，到 2026 年將成長至 1,463 億美元，到 2032 年將達到 1997.3 億美元，複合年成長率為 5.38%。

主要市場統計數據
基準年 2025 1383.7億美元
預計年份：2026年 1463億美元
預測年份 2032 1997.3億美元
複合年成長率 (%) 5.38%

為感染疾病物市場制定一個綜合框架，以明確策略決策者在臨床、營運、監管和創新方面的優先事項。

感染疾病物領域處於緊迫的公共衛生需求與複雜的商業性動態的交匯點，臨床需求與供應鏈現實和快速發展的科學技術之間存在衝突。本文透過建立影響產業、醫療服務提供者和政策制定者決策的關鍵主題支柱，系統地梳理了這種交匯點。治療方法，並透過總結決定短期優先事項的結構性、臨床和監管因素，引導讀者閱讀以下章節。

快速診斷、新型治療方法和具有韌性的供應鏈策略如何重塑感染疾病物領域的臨床決策和商業模式。

抗感染疾病醫學領域正經歷一場變革性的重塑，這場變革涵蓋科學、商業性和製度等多個層面。精準診斷和快速分子檢測技術的進步使得更早期、更有針對性的治療方法成為可能，從而改變了處方模式和對特定藥物類別的需求。同時，創新正從漸進式改進加速發展到新型治療方法和基於機制的策略，以應對抗藥性病原體，並在生物製藥公司、診斷開發商和臨床網路之間催生出新的夥伴關係模式。因此，價值鏈正從以產品為中心的模式演變為提供整合治療、診斷、合理用藥方案和數位化監測平台的綜合治療方法。

評估到 2025 年累積關稅調整對抗感染疾病藥物整個價值鏈的籌資策略、業務永續營運和投資決策的重大影響。

到2025年，累積貿易政策措施和關稅調整正在影響整個感染疾病物供應鏈的成本結構和策略規劃，尤其是那些依賴跨境採購中間體和成品的公司。雖然關稅政策並非對所有治療領域都一視同仁，但其累積影響正在提高人們對單一供應商脆弱性的認知，並加速減少對地理位置集中供應商依賴的步伐。因此，採購團隊和生產主管越來越重視供應商多元化、建立本地生產能力以及透過合約保障措施來應對關稅相關的不確定性。

綜合細分分析揭示治療領域、臨床適應症、給藥途徑、通路和差異化策略對最終使用者的影響。

一套精細的細分框架揭示了臨床需求、產品特性和分銷管道動態相互作用，從而形成差異化策略重點的領域。基於產品類型，該領域涵蓋了廣泛的分類，包括抗生素、抗真菌藥物、抗寄生蟲藥物和抗病毒藥物。在抗生素領域，策略重點領域包括Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類、磺胺類藥物和四環黴素，每種藥物都有其獨特的抗藥性特徵，並對合理用藥產生影響。抗真菌藥物領域包括Allylamines、Azole類、Echinocandins和Polyenes，這些藥物在抗菌頻譜、毒性特徵以及是用於住院或門診病人存在差異。抗寄生蟲藥包括驅蟲藥、抗瘧疾藥和抗原生動物藥，區域流行病學影響需求模式。另一方面，抗病毒藥物包括神經氨酸酶抑制劑、核苷類似物、聚合酵素抑制劑和蛋白酶抑制劑，這反映了其作用機制的多樣性以及在慢性病和急性疾病中的應用。

區域比較趨勢突顯了流行病學、製造業生態系統、監管方法和醫療保健財務如何塑造不同的策略重點。

區域趨勢塑造了美洲、歐洲、中東和非洲以及亞太地區的感染疾病物格局，將流行病學、生產能力、監管方法和支付方行為以獨特的模式聯繫起來。在美洲，醫療保健系統憑藉其先進的醫院功能、大規模的門診市場和成熟的學名藥生產體系，既需要新的療法，也需要最佳化的籌資策略來維持藥物的可及性。在歐洲、中東和非洲，監管協調的努力與多樣化的醫療保健資金籌措模式並存，並且高度重視合理使用抗菌藥物，影響藥物目錄的選擇和報銷途徑。

已成立的製藥公司、非專利生產商、生物技術創新者和契約製造的策略行動和競爭定位將決定未來的主導。

在感染疾病物領域，各公司的發展軌跡正在分化。傳統製藥公司、學名藥領導企業、生物技術創新者和契約製造採取差異化策略，以獲取臨床和商業性價值。大型成熟製藥公司利用其廣泛的產品組合、豐富的監管經驗和全球分銷網路，為後期臨床項目提供支持，並維持關鍵產品的持續供應。同時，學名藥生產商和專業化學品生產商是穩定供應的關鍵合作夥伴，他們專注於成本效益高的生產、活性成分的大規模生產以及對需求激增的快速反應。

產業領導者面臨的實際策略挑戰是，如何協調診斷、管理、靈活製造和循證契約，以建立永續優勢。

產業領導者應優先採取一系列高影響力措施，以兼顧臨床價值、業務永續營運和商業性可行性。首先，透過將快速診斷和合理用藥方案與藥物導入相結合，並確保新藥和現有藥物的有效和持續使用，從而維持藥物的長期臨床效用。其次，透過採購多元化和投資於生產柔軟性，在保持成本競爭力的同時，降低地緣政治和關稅相關風險。合約機制和策略夥伴關係可以加速這一轉型。第三，與保險公司和醫療保健系統採用基於適應症和療效的合約模式，以協調合理用藥的獎勵，並展現藥物的實際價值。

為了檢驗這些見解，我們採用了一種穩健的混合方法研究途徑，結合了初步訪談、監管和臨床文獻綜述、案例研究和情境映射。

本分析的調查方法結合了多方面的證據、專家見解和結構化整合，旨在提供可操作的洞見。主要研究包括對製藥、生物技術、製造和臨床領域的管理人員進行深度訪談，並輔以與監管專家和供應鏈從業人員的諮詢，以檢驗營運影響。次要研究則包括對同行評審文獻、監管指導文件、臨床治療指南和公開的企業資訊披露進行系統性回顧，以闡明趨勢並提供多方面的檢驗，從而對研究結果進行深入分析。

整合是平衡緊急復原措施與長期創新和管理優先事項的結論，旨在指導策略性投資和政策參與。

總之，在診斷技術進步、價值鏈需求演變以及創新模式策略轉變的驅動下，感染疾病物產業正經歷著一場深刻的變革。這些因素既帶來了挑戰，也帶來了機會。挑戰包括抗菌素抗藥性的動態變化、日益複雜的採購流程以及政策的不確定性。另一方面，機會則包括整合診斷和治療方案、建立穩健的生產夥伴關係關係以及將臨床價值與支付結果相結合的新型商業模式。本文的分析闡明了應將資源集中投入哪些領域，以維持藥物的可及性並提供差異化的治療價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：感染疾病物市場：依產品類型分類

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺
    • Fluoroquinolones
    • 大環內酯類
    • 磺胺類藥物
    • 四環黴素
  • 抗真菌藥物
    • Allylamines
    • Azole
    • Echinocandins
    • Polyenes
  • 抗寄生蟲藥物
    • 驅蟲
    • 抗瘧疾藥
    • 原生動物治療藥物
  • 抗病毒藥物
    • 神經氨酸酶抑制劑
    • 核苷類似物
    • 聚合酵素抑制劑
    • 蛋白酶抑制劑

第9章：感染疾病物市場：依適應症分類

  • 血液感染疾病
  • 胃腸道感染疾病
  • 呼吸道感染疾病
    • 支氣管炎
    • 社區型肺炎
    • 院內肺炎
  • 皮膚和軟組織感染疾病
  • 尿道感染

第10章：感染疾病物市場：依給藥途徑分類

  • 吸入
  • 口服
  • 腸外
  • 外用

第11章：感染疾病物市場：依分銷管道分類

  • 線上
  • 離線

第12章：感染疾病物市場：依最終用戶分類

  • 診所
  • 居家照護設施
  • 醫院

第13章：感染疾病物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：感染疾病物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：感染疾病物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國感染疾病物市場

第17章：中國感染疾病市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline plc（GSK）
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • Shionogi & Co Ltd
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc
  • Wockhardt Limited
  • Zydus Lifesciences Limited
Product Code: MRR-1A1A064C0031

The Anti-infectives Market was valued at USD 138.37 billion in 2025 and is projected to grow to USD 146.30 billion in 2026, with a CAGR of 5.38%, reaching USD 199.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 138.37 billion
Estimated Year [2026] USD 146.30 billion
Forecast Year [2032] USD 199.73 billion
CAGR (%) 5.38%

Comprehensive framing of the anti-infectives landscape to clarify clinical, operational, regulatory, and innovation priorities for strategic decision-makers

The anti-infectives domain stands at the intersection of urgent public health need and complex commercial dynamics, where clinical imperatives collide with supply chain realities and rapid scientific progress. This introduction frames that convergence by establishing the critical thematic pillars that shape decision-making across industry, healthcare providers, and policy sponsors. It highlights the dual challenge of addressing antimicrobial resistance while ensuring resilient access to established and novel therapies, and it orients readers toward the sections that follow by summarizing the structural, clinical, and regulatory forces that will determine near-term priorities.

In the current environment, stakeholders must balance short-term operational responses with mid- to long-term strategic investments. Accordingly, this section positions the narrative around four core dimensions: therapeutic innovation and repurposing, manufacturing and procurement resilience, regulatory and market access dynamics, and integrated diagnostic stewardship. These dimensions serve as the lenses through which subsequent analyses of segmentation, regional differences, company strategy, and policy impacts should be interpreted. By clarifying the interplay among scientific advances, distribution channels, and care settings, this introduction prepares leaders to translate evidence into prioritized action.

Finally, the introduction emphasizes evidence-driven decision-making and cross-sector collaboration as foundational principles. It underscores the necessity of linking clinical practice with supply chain design and market intelligence, thereby creating a consistent frame for the deeper insights and recommendations presented in the rest of the executive summary.

How rapid diagnostics, novel therapeutic modalities, and resilient supply chain strategies are reshaping clinical decision making and commercial models across anti-infectives

The anti-infectives landscape is being reshaped by transformative shifts that are simultaneously scientific, commercial, and systemic. Advances in precision diagnostics and rapid molecular testing are enabling earlier and more targeted therapeutic choices, which in turn alter prescribing patterns and demand for specific classes of agents. At the same time, innovation has accelerated beyond incremental modifications toward novel modalities and mechanism-based therapies that address resistant pathogens, creating new partnership models between biopharma, diagnostic developers, and clinical networks. As a result, value chains are evolving from product-centric models to integrated solution offerings that combine therapeutics with diagnostics, stewardship programs, and digital monitoring platforms.

Concurrently, supply chain strategies are undergoing structural rebalancing. Stakeholders are increasingly prioritizing manufacturing flexibility, dual sourcing of critical active pharmaceutical ingredients, and strategic inventory policies to mitigate geopolitical and logistics risks. Regulatory environments are adapting to these shifts through expedited pathways for clinically urgent agents and greater emphasis on real-world evidence to support treatment decisions. Market access pressures are also stimulating new contracting approaches, including indication-specific agreements and outcome-based pricing that align incentives for appropriate use.

Taken together, these transformational changes are creating opportunities for nimble organizations to differentiate through integrated offerings, durable manufacturing strategies, and closer alignment with clinical workflows. The net effect is a more interconnected ecosystem in which scientific innovation, operational resilience, and data-driven market access strategies determine competitive positioning and public health impact.

Assessment of how cumulative tariff adjustments through 2025 have materially influenced sourcing strategies, operational resilience, and investment decisions across the anti-infectives value chain

Cumulative trade policy measures and tariff adjustments enacted through 2025 have influenced cost structures and strategic planning across the anti-infectives supply chain, particularly for firms reliant on cross-border sourcing of intermediates and finished products. While tariff policy does not uniformly apply to all therapeutic categories, its cumulative effect has been to raise awareness of single-source vulnerabilities and to accelerate initiatives that reduce dependence on geographically concentrated suppliers. Consequently, procurement teams and manufacturing executives have increasingly prioritized supplier diversification, localized capacity building, and contractual protections to manage tariff-driven uncertainty.

Moreover, tariff-related pressures have shifted the calculus for capital investment and partnership formation. Companies evaluating new manufacturing sites or expansion projects must now weigh potential tariff exposure alongside labor, regulatory, and logistics considerations. At the same time, some firms have pursued strategic vertical integration or established closer contractual relationships with contract development and manufacturing organizations to buffer against external trade shocks. These responses reflect an operational pivot toward resilience rather than solely cost minimization.

Finally, regulatory and policy responses to tariff pressures have introduced additional considerations. In many jurisdictions, policymakers have shown a willingness to implement targeted exemptions or engagement programs to preserve access to essential medicines, which has moderated some of the immediate impacts for critical items. Nevertheless, the cumulative impact through 2025 remains a material factor in procurement strategy, supply chain design, and financial planning across the anti-infectives ecosystem, prompting sustained emphasis on scenario planning and adaptive sourcing frameworks.

Integrated segmentation analysis revealing therapeutic classes, clinical indications, administration routes, distribution channels, and end-user implications for differentiated strategy

A nuanced segmentation framework illuminates where clinical need, product characteristics, and channel dynamics interact to create differentiated strategic priorities. Based on product type, the field spans broad classes such as antibiotics, antifungals, antiparasitics, and antivirals; within antibiotics, strategic focus areas include aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines, each with distinct resistance profiles and stewardship implications. The antifungal segment includes allylamines, azoles, echinocandins, and polyenes, which vary by spectrum of activity, toxicity profiles, and inpatient versus outpatient application. Antiparasitics cover anthelmintics, antimalarials, and antiprotozoals, with regional epidemiology driving demand patterns, while antivirals encompass neuraminidase inhibitors, nucleoside analogues, polymerase inhibitors, and protease inhibitors, reflecting diverse mechanisms and both chronic and acute use cases.

Based on indication, the market separates along clinical presentations such as bloodstream infections, gastrointestinal infections, respiratory infections, skin and soft tissue infections, and urinary tract infections; respiratory infections further distinguish bronchitis, community-acquired pneumonia, and hospital-acquired pneumonia, each of which involves unique diagnostic pathways and settings of care. Based on route of administration, therapeutic choices are organized by inhalation, oral, parenteral, and topical delivery, which influence prescribing patterns, adherence considerations, and distribution logistics. Based on distribution channel, medicines are delivered through drug stores, hospital pharmacies, online pharmacies, and retail pharmacies, with each channel presenting different reimbursement dynamics and patient access considerations. Based on end user, adoption and purchasing behavior diverge across clinics, home care settings, and hospitals, shaping contracting strategies, clinical training needs, and point-of-care diagnostics integration.

Integrating these segmentation layers reveals priority intersections where development investment, commercial focus, and supply chain resilience yield the greatest strategic return. For example, agents intended for hospital-acquired respiratory infections that require parenteral administration will necessitate robust hospital pharmacy alignment and inpatient stewardship programs, whereas oral antivirals for outpatient care will prioritize retail and online pharmacy distribution, adherence solutions, and payer engagement.

Comparative regional dynamics highlighting how epidemiology, manufacturing ecosystems, regulatory approaches, and healthcare financing shape differentiated strategic priorities

Regional dynamics shape the anti-infectives environment by aligning epidemiology, manufacturing capacity, regulatory approaches, and payer behavior in distinct patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems combine advanced hospital capabilities with large outpatient markets and established generics manufacturing, creating demand for both novel therapeutics and optimized procurement strategies that preserve access. Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied healthcare financing models and a pronounced emphasis on antimicrobial stewardship, which influences formulary decisions and reimbursement pathways.

In the Asia-Pacific region, rapid expansion of manufacturing capacity, strong generics competitiveness, and shifting R&D investment are key features; these dynamics are coupled with heterogeneous regulatory systems and varying levels of healthcare infrastructure, which together drive both export-oriented production and growing regional demand for innovative treatments. Transitional economies within these regions are shaping procurement models that balance cost containment with the need to upgrade clinical diagnostics and supply chain resilience. Across all regions, cross-border collaboration on surveillance and resistance monitoring is increasingly important, and regional policy initiatives often determine priority access for specific therapeutic classes.

Taken together, these regional insights emphasize that strategies must be tailored to local regulatory norms, manufacturing ecosystems, and clinical practice patterns. Companies that align product formulation, distribution models, and stewardship partnerships to regional realities will be better positioned to achieve sustained clinical adoption and resilient supply operations.

Strategic behaviors and competitive positioning of established pharmaceutical firms, generics manufacturers, biotech innovators, and contract manufacturers shaping future leadership

Company trajectories within anti-infectives are diverging as traditional pharmaceutical firms, generics leaders, biotech innovators, and contract manufacturers adopt differentiated strategies to capture clinical and commercial value. Established large-pharma players are leveraging broad portfolios, regulatory experience, and global distribution networks to support late-stage clinical programs and to maintain supply continuity for essential lines. Conversely, generics manufacturers and specialized chemical producers are concentrating on cost-efficient production, scale in active pharmaceutical ingredients, and rapid response to demand spikes, making them pivotal partners for supply security.

Biotech and small-cap innovators are focusing on novel mechanisms of action, narrow-spectrum agents, and adjunctive therapies that enable more targeted approaches to resistant pathogens. These firms frequently engage in partnerships with diagnostic companies and clinical networks to demonstrate value through precision prescribing. Contract development and manufacturing organizations are expanding capabilities to offer flexible, small-batch production and regulatory support, thereby enabling faster commercialization for both emergent agents and reformulated legacy products. Across company types, M&A, licensing, and co-development agreements are being used strategically to bridge R&D gaps, secure manufacturing footprint, and accelerate access to complementary technologies.

In sum, competitive advantage is increasingly derived from the ability to integrate clinical differentiation with operational resilience and payer-aware commercial models. Firms that combine targeted innovation with supply chain agility and strong clinical evidence generation are positioned to lead, while those that lag in diagnostic integration or flexible manufacturing risk erosion of market relevance.

Practical strategic imperatives for industry leaders to align diagnostics, stewardship, flexible manufacturing, and evidence-based contracting for sustainable advantage

Industry leaders should prioritize a set of high-impact actions that align clinical value with operational resilience and commercial viability. First, integrate rapid diagnostics and stewardship programs with therapeutic rollouts to ensure that new and existing agents are used effectively and sustainably, thereby preserving long-term clinical utility. Second, diversify sourcing and invest in manufacturing flexibility to mitigate geopolitical and tariff-related risks while preserving cost competitiveness; contractual mechanisms and strategic partnerships can accelerate this transition. Third, adopt indication- and outcome-based contracting models with payers and health systems to align incentives for appropriate use and to demonstrate real-world value.

Further, invest selectively in novel mechanisms and platform technologies that address resistant pathogens, while leveraging strategic alliances for accelerated clinical development and market entry. Commit to comprehensive surveillance and data-sharing initiatives that support both public health objectives and commercial decision-making, enabling more precise targeting of clinical trials and post-market evidence generation. Finally, ensure organizational readiness through cross-functional governance that links R&D, regulatory affairs, supply chain, and commercial teams to expedite decision cycles and reduce time-to-clinic or time-to-market for priority assets.

By implementing these actions in a coordinated manner, leaders can balance short-term access imperatives with long-term stewardship and innovation goals, transforming systemic challenges into sources of competitive advantage.

Robust mixed-methods research approach combining primary interviews, regulatory and clinical literature review, case studies, and scenario mapping to validate insights

The research methodology underpinning this analysis combines multi-source evidence, expert input, and structured synthesis to deliver actionable insights. Primary research included in-depth interviews with senior executives across pharmaceutical, biotech, manufacturing, and clinical backgrounds, supplemented by consultations with regulatory specialists and supply chain practitioners to validate operational implications. Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, clinical treatment guidelines, and publicly available corporate disclosures to contextualize trends and triangulate findings.

Analytical approaches incorporated qualitative thematic analysis and scenario-based supply chain mapping to explore how policy changes, tariff dynamics, and clinical innovation could interact under alternative conditions. Case studies were used to illustrate best practices in manufacturing resilience, diagnostic-therapeutic integration, and stewardship program implementation. Finally, internal expert panels reviewed draft findings to ensure relevance for commercial strategy and to refine recommendations according to operational feasibility and regulatory realities.

This mixed-methods approach emphasizes transparency, triangulation, and practitioner validation, providing stakeholders with a robust evidence base for strategic planning without relying on proprietary forecasting that could obscure operational nuances.

Concluding synthesis that balances urgent resilience measures with long-term innovation and stewardship priorities to guide strategic investment and policy engagement

In conclusion, the anti-infectives sector is undergoing a period of substantive transformation driven by diagnostic advances, evolving supply chain imperatives, and strategic shifts in innovation models. These forces are creating both challenges and opportunities: challenges in the form of resistance dynamics, procurement complexity, and policy uncertainty; and opportunities in the form of integrated diagnostic-therapeutic solutions, resilient manufacturing partnerships, and novel commercial models that align clinical value with payment outcomes. The synthesis presented here highlights where to focus resources to preserve access and to deliver differentiated therapeutic value.

Organizations that proactively integrate stewardship with go-to-market strategies, diversify their manufacturing and sourcing footprint, and build evidence generation frameworks aligned with payer expectations will be best positioned to navigate the evolving landscape. Collaboration across public and private stakeholders, investment in flexible production capabilities, and commitment to targeted R&D will be essential to ensuring sustained patient access and long-term therapeutic effectiveness. The recommendations in this summary are designed to be operationally actionable and to support decision-makers as they translate insight into measurable strategic moves.

Ultimately, the path forward requires balancing near-term operational resilience with long-term investments in innovation and stewardship, ensuring that therapeutic advances are preserved and widely accessible for the populations that need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Allylamines
    • 8.2.2. Azoles
    • 8.2.3. Echinocandins
    • 8.2.4. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Anthelmintics
    • 8.3.2. Antimalarials
    • 8.3.3. Antiprotozoals
  • 8.4. Antivirals
    • 8.4.1. Neuraminidase Inhibitors
    • 8.4.2. Nucleoside Analogues
    • 8.4.3. Polymerase Inhibitors
    • 8.4.4. Protease Inhibitors

9. Anti-infectives Market, by Indication

  • 9.1. Bloodstream Infections
  • 9.2. Gastrointestinal Infections
  • 9.3. Respiratory Infections
    • 9.3.1. Bronchitis
    • 9.3.2. Community Acquired Pneumonia
    • 9.3.3. Hospital Acquired Pneumonia
  • 9.4. Skin And Soft Tissue Infections
  • 9.5. Urinary Tract Infections

10. Anti-infectives Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
  • 10.4. Topical

11. Anti-infectives Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Anti-infectives Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-infectives Market

17. China Anti-infectives Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc
  • 18.7. Astellas Pharma Inc
  • 18.8. AstraZeneca plc
  • 18.9. Aurobindo Pharma Limited
  • 18.10. Bayer AG
  • 18.11. Biocon Limited
  • 18.12. Boehringer Ingelheim GmbH
  • 18.13. Bristol Myers Squibb
  • 18.14. Cipla Limited
  • 18.15. Dr. Reddy's Laboratories Ltd
  • 18.16. Eli Lilly and Company
  • 18.17. F. Hoffmann-La Roche Ltd
  • 18.18. Gilead Sciences Inc
  • 18.19. GlaxoSmithKline plc (GSK)
  • 18.20. Glenmark Pharmaceuticals Limited
  • 18.21. Johnson & Johnson
  • 18.22. Lupin Limited
  • 18.23. Merck & Co Inc
  • 18.24. Novartis AG
  • 18.25. Otsuka Pharmaceutical Co Ltd
  • 18.26. Pfizer Inc
  • 18.27. Sanofi
  • 18.28. Shionogi & Co Ltd
  • 18.29. Sun Pharmaceutical Industries Limited
  • 18.30. Teva Pharmaceutical Industries Limited
  • 18.31. Viatris Inc
  • 18.32. Wockhardt Limited
  • 18.33. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)